The FDA has authorized Abbott’s Libre Duo 10 Day, the first continuous glucose and ketone monitoring system, in the United States. The new biowearable continuously monitors glucose while also tracking rising ketone levels that could lead to diabetic ketoacidosis (DKA), providing an additional data without requiring separate blood or urine ketone testing. Abbott plans to launch Libre Duo 10 Day in the U.S. later this year.

Abbott plans to release two versions; Libre Duo 10 Day for those 2 years and older, and Libre Duo, which lasts up to 15 days, and is for adults 18 years and older. Both models received a CE Mark earlier this year, approving the sensors for use in specific European markets.

Unlike traditional ketone testing, which provides a single point-in-time measurement, Libre Duo 10 Day monitors ketones in the background and is designed to alert users when levels are rising. The system is intended for people ages 2 and older, including those with type 1 and type 2 diabetes. It offers up to 10 days of wear and works with the latest-generation Libre app.

Abbott is also working to connect Libre Duo 10 Day with automated insulin delivery systems. The company already has ongoing partnerships and expects compatibility with Beta Bionics’ iLet and Sequel Med Tech’s twiist by the end of 2026, followed by devices from Insulet (Omnipod) and Tandem in 2027. Abbott and MiniMed are also collaborating on an exclusive integration between Abbott-manufactured dual glucose-ketone sensors and MiniMed systems, expected in 2027.

Dexcom, the makers of the Dexcom G7 and G7 15 day CGM, is also developing a dual-hormone sensor, designed to monitor glucose and potassium levels. There currently is no at-home test for potassium levels, so tracking this second biomarker could help prevent hyperkalemia, or high levels of potassium in the blood.

Would you use a dual glucose-ketone sensor? Let us know why in the comments!